期刊文献+

siRNA沉默USP22基因对胶质瘤细胞增殖的抑制作用 被引量:4

si RNA-mediated silencing of the USP22 gene inhibits cell proliferation in human glioma cells
下载PDF
导出
摘要 目的探讨小干扰RNA(si RNA)沉默泛素特异性肽酶22(ubiquitin specific protease 22,USP22)对胶质瘤细胞增殖的影响和作用机制。方法合成USP22 si RNA及阴性对照si RNA(control si RNA),用脂质体Lipofectamine 2000转染至人胶质瘤U87和U251细胞,分别设为实验组和阴性对照组。通过逆转录聚合酶链反应(RT-PCR)和Western blot检测两组胶质瘤细胞USP22 mRNA和蛋白表达水平的变化。采用四甲基偶氮唑蓝比色法(MTT法)检测USP22 si RNA对两组胶质瘤细胞的增殖抑制率。流式细胞术定量检测USP22 si RNA对胶质瘤细胞凋亡及细胞周期分布的影响。Western blot检测胶质瘤细胞凋亡蛋白和周期调控蛋白的表达。结果与阴性对照组比较,实验组胶质瘤细胞中USP22 mRNA和蛋白表达显著下降(P<0.05),细胞增殖明显受到抑制(P<0.05),凋亡率明显上升(P<0.05),细胞周期中G2/M期的细胞比例明显增高(P<0.05)。Western blot结果显示:细胞凋亡蛋白Procaspase-3、Procaspase-8、Procaspase-9表达明显下降(P<0.05);细胞周期蛋白CDK1、CDK2、Cyclin B1表达水平明显下降(P<0.05),Cyclin D1表达水平无明显变化(P>0.05)。结论 USP22基因在胶质瘤细胞的增殖中发挥重要作用,其机制可能为调节细胞凋亡和细胞周期。 Objective To explore the influence and action mechanism of ubiquitin-specific protease 22(USP22) gene silencing by small interference RNA( si RNA) on proliferation of human glioma cells. Methods USP22 si RNA and a negative control si RNA were designed and transfected into glioma cell lines U87 and U251 by using Lipofectamine 2000. The cells which were transfected with USP22 si RNA and control si RNA were set as experimental and negative control groups respectively. RT-PCR and Western blot were used to detect the expressions of USP22 mRNA and protein in glioma cells in two groups. Cell proliferation was measured by MTT. The apoptosis rate and the distribution of cell cycle of U87 and U251 were determined by flow cytometry. The apoptosis proteins and cell cycle proteins were detected by Western blot. Results Compare with negative control group, the expressions of USP mRNA and protein were decreased significantly(P〈0.05), cell proliferation was obviously inhibited(P〈0.05), apoptosis rate rose markedly(P〈0.05), the proportion of G2/M in cell cycle was higher(P〈0.05). Western blot results showed that the expressions of apoptosis proteins such as Procaspase-3, Procaspase-8 and Procaspase-9 were decreased(P〈0.05), cell cycle proteins such as CDK1, CDK2 and Cyclin B1decreased(P〈0.05), but the expression of Cyclin D1 remained stable(P〉0.05). Conclusion USP22 gene plays a key role in the proliferation of human glioma cells by regulating the apoptosis and cell cycle.
出处 《中国微侵袭神经外科杂志》 CAS 2015年第9期419-423,共5页 Chinese Journal of Minimally Invasive Neurosurgery
关键词 神经胶质瘤 泛素特异性肽酶22 RNA干扰 细胞增殖 细胞凋亡 细胞周期 gliomas ubiquitin specific protease 22 RNA interference cell proliferation cell apoptosis cell cycle
  • 相关文献

参考文献15

  • 1Field KM,Drummo nd KJ,Yilmaz M,et al.Clinical trial participation and outcome for patients with glioblastoma:multivariate analysis from a comprehensive dataset[J].J Clin Neurosci,2013,20(6):783-789.
  • 2杭春华.脑胶质瘤的治疗进展[J].中国微侵袭神经外科杂志,2011,16(9):429-432. 被引量:16
  • 3Kapoor S.Usp22 and its evolving role in systemic carcinogenesis[J].Lung Cancer,2013,79(2):191.
  • 4Li J,Wang Z,Li Y.USP22 nuclear expression is significantly associated with progression and unfavorable clinical outcome in human esophageal squamous cell carcinoma[J].J Cancer Res Clin Oncol,2012,138(8):1291-1297.
  • 5Piao S,Ma J,Wang W,et al.Increased expression of USP22 is associated with disease progression and patient prognosis of salivary duct carcinoma[J].Oral Oncol,2013,49(8):796-801.
  • 6Yang DD,Cui BB,Sun LY,et al.The co-expression of USP22 and BMI-1 may promote cancer progression and predict therapy failure in gastric carcinoma[J].Cell Biochem Biophys,2011,61(3):703-710.
  • 7Ning Z,Wang A,Liang J,et al.USP22 promotes epithelialmesenchymal transition via the FAK pathway in pancreatic cancer cells[J].Oncol Rep,2014,32(4):1451-1458.
  • 8Zhang Y,Yao L,Zhang X,et al.Elevated expression of USP22 in correlation with poor prognosis in patients with invasive breast cancer[J].J Cancer Res Clin Oncol,2011,137(8):1245-1253.
  • 9Li ZH,Yu Y,Du C,et al.RNA interference-mediated USP22 gene silencing promotes human brain glioma apoptosis and induces cell cycle arrest[J].Oncol Lett,2013,5(4):1290-1294.
  • 10Atanassov BS,Dent SY.USP22 regulates cell proliferation by deubiquitinating the transcriptional regulator FBP1[J].EMBO Rep,2011,12(9):924-930.

二级参考文献20

  • 1Li B, Yuan M, Kim IA, et al. Mutant epidermal growth factor receptor displays increased signaling through the phosphatidylinositol-3 kinase/AKT pathway and promotes radioresistance in cells of astrocytic origin [J]. Oncogene, 2004, 23(26): 4594-4602.
  • 2Kesari SN, Ramakrishna N, Sauvageot C, et al. Targeted molecular therapy of malignant gliomas [J]. Curr Neurol Neurosci Rep, 2005, 5(3): 186-197.
  • 3Rich JN, Reardon DA, Peery T, et al. Phase II trial of gefitinib in recurrent glioblastoma [J]. J Clin Oncol, 2004, 22(1): 133-142.
  • 4Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors [J]. N Engl J Med, 2005, 353 (19): 2012- 2024.
  • 5Spector NL, Xia W, Burris H 3rd, et al. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB 1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies [J]. J Clin Oncol, 2005, 23(11): 2502-2512.
  • 6Traxler P, Allegrini PR, Brandt R, et al. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity [J]. Cancer Res, 2004, 64(14): 4931-4941.
  • 7Raymond E, Brandes A.A, Dittrich C, et al. Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study [J]. J Clin Oncol, 2008, 26(28): 4659-4665.
  • 8Cloughesy TF, Wen PY, Robins HI, et al. Phase II trial of tipifamib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study [J]. J Clin Oncol, 2006, 24(22): 3651-3656.
  • 9Sathomsumetee S, Reardon DA, Desjardins A, et al. Molecularly targeted therapy for malignant glioma [J]. Cancer, 2007, 110(1): 13-24.
  • 10Guiu S, Taillibert S, Chinot O, et al. Bevacizumab/ irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study [J]. Rev Neurol (Paris), 2008, 164(6-7): 588-594.

共引文献15

同被引文献16

引证文献4

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部